Compare Natera Inc. Common Stock (NTRA) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Invesco Preferred ETF — how do they compare? Natera Inc. Common Stock trades at $392.22 (market cap $57.03B), while Invesco Preferred ETF trades at $9.93 (market cap $3.58B). The key difference: Natera Inc. Common Stock is far larger — about 15.9× Invesco Preferred ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Invesco Preferred ETF for 96 Days on average.
| NTRA | PGX | |
|---|---|---|
Market Cap | $57.03B | $3.58B |
Volume | 1,131,157 | 10,976,352 |
Sector | Health | — |
52-Week High | $425.64 | $11.61 |
52-Week Low | $179.42 | $9.95 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PGX trades at $9.98 with a modest 0.3% daily gain, though technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces significant resistance at $10, which also serves as multiple support levels. Recent corporate actions include scheduled dividends of $0.06 per share for H2-2026, providing income potential for shareholders.
The outlook remains cautious given the bearish technical setup and lack of available fundamental data. While dividend payments offer some investor appeal, the absence of key valuation metrics and financial ratios creates uncertainty about the company's underlying business performance and competitive positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
